Capitol Hill Sen. Durbin weighs in on the controversy about dosage of Amgen drug sotorasib May 17, 2024Vol.50 No.20By Paul Goldberg
Drugs & Targets FDA, EMA grant Orphan Drug Designation to Carthera for carboplatin with SonoCloud technology in glioma May 17, 2024Vol.50 No.20
Guest Editorial OCE’s Project 5 in 5 seeks to inspire pragmatic innovation May 10, 2024Vol.50 No.19By Steven C. Cunningham, Donna R. Rivera, Richard Pazdur, Kelly J. Norsworthy and Jennifer Gao
Health EquityWhite House Citing need for “more conversations” on menthol, White House scuttles move to ban the flavor favored by Black smokers May 03, 2024Vol.50 No.18By McKenzie Prillaman
Drugs & Targets FDA issues additional draft guidance on eligibility criteria for cancer drug clinical trials May 03, 2024Vol.50 No.18
Regulatory News ODAC unanimously upholds MRD as early endpoint across all settings in multiple myeloma April 26, 2024Vol.50 No.17By Jacquelyn Cobb
Conversation with The Cancer Letter Clearing the path for MRD as early endpoint in multiple myeloma April 26, 2024Vol.50 No.17By Jacquelyn Cobb
Drugs & Targets FDA approves Anktiva for non-muscle-invasive bladder cancer April 26, 2024Vol.50 No.17
